Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 46.36% | 126.64% | 101.01% | 75.22% | 46.28% |
| Total Depreciation and Amortization | 1.93% | 1.64% | 0.54% | -0.96% | -3.23% |
| Total Amortization of Deferred Charges | 6.50% | 4.27% | 12.17% | 22.92% | 32.81% |
| Total Other Non-Cash Items | 270.74% | 47.45% | 102.54% | 195.62% | 78.48% |
| Change in Net Operating Assets | 90.95% | 86.14% | -17.46% | -214.14% | -514.79% |
| Cash from Operations | 449.89% | 281.69% | 177.41% | 133.53% | 57.19% |
| Capital Expenditure | -56.59% | -40.59% | 19.82% | 25.26% | 42.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -2.65% | 30.44% |
| Cash from Investing | -104.78% | -104.11% | -114.25% | -0.84% | 35.66% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 200.00% |
| Issuance of Common Stock | 258.60% | 317.02% | 1,184.77% | 1,743.88% | 518.22% |
| Repurchase of Common Stock | -111.11% | -139.76% | -191.27% | -162.70% | -152.55% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -898.40% |
| Cash from Financing | 455.85% | 363.01% | -68.51% | -65.10% | -105.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,849.34% | 1,322.61% | 866.07% | 152.34% | -85.94% |